Breaking News

Matica Bio, Cirsium Biosciences Enter AAV Manufacturing Pact

Matica Bio to provide analytical and downstream support that complements Cirsium's plant-based AAV technology.

Matica Biotechnology, Inc., a CDMO specializing in viral vector production, and Cirsium Biosciences, a biotechnology company developing a plant-based AAV (adeno-associated virus) technology, entered a non-exclusive strategic partnership. This collaboration leverages Cirsium’s hybrid hub-and-spoke manufacturing model, which combines internal plant-based AAV production capabilities with downstream collaborators to maximize flexibility, scalability, and distribution. Through this agreement...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters